Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. | Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN